{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:58:10Z","timestamp":1791849490815,"version":"4.3.4"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Currently, the axillary management strategy of omitting axillary lymph node dissection (ALND) in early-stage breast cancer (BC) patients with cT1-2, clinically node-negative (cN0), and sentinel lymph node biopsy (SLNB) revealing 1\u20132 sentinel lymph nodes (SLNs) macro-metastases remains controversial. This study aims to systematically evaluate the safety of omitting ALND in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered with the registration number: CRD42025645388. A systematic literature search was conducted across five electronic databases (PubMed, Web of Science, Cochrane Library, Ovid Medline, and Embase) from inception through December 2024. Randomized controlled trials (RCTs) and cohort studies meeting the predefined eligibility criteria were included. Primary outcomes included disease-free survival (DFS) and overall survival (OS). The association between ALND omission and long-term outcomes was assessed using pooled hazard ratios (HRs) with 95% confidence intervals (CIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifteen studies (6 RCTs, 9 cohort studies) involving 33,599 patients in the SLNB-only group and 95,711 controls receiving SLNB+ALND were analyzed. No significant differences in DFS (HR = 0.99, 95%CI:0.85-1.14, p=0.857) or OS (HR = 1.03, 95%CI: 0.92-1.14 p=0.251) were observed in both groups. Subgroup analyses by follow-up duration (5-years and 10-years), study design (RCTs and cohort studies), and region (Eastern and Western) showed no survival differences between the experimental and control groups. (all p values are greater than 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Omitting ALND is safe for early-stage BC patients with cT1-2, cN0, and 1\u20132 SLNs macro-metastases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42025645388.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1620034","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:17:47Z","timestamp":1758773867000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety analysis of omitting axillary lymph node dissection in early-stage breast cancer with 1\u20132 sentinel lymph nodes macro-metastases: a meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxia","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changrui","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.02.08","article-title":"Advances in regional nodal management of early-stage breast cancer","volume":"36","author":"Bi","year":"2024","journal-title":"Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2020.09.001","article-title":"Axillary surgery in breast cancer: An updated historical perspective","volume":"47","author":"Magnoni","year":"2020","journal-title":"Semin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.breast.2022.02.013","article-title":"Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial","volume":"63","author":"Appelgren","year":"2022","journal-title":"Breast"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00099","article-title":"Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021203935","article-title":"Beneficial effect of consecutive screening mammography examinations on mortality from breast cancer: A prospective study","volume":"299","author":"Duffy","year":"2021","journal-title":"Radiology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.11.018","article-title":"De-escalating axillary surgery in early-stage breast cancer","volume":"62","author":"Hersh","year":"2022","journal-title":"Breast"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0140-6736(97)01004-0","article-title":"Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes","volume":"349","author":"Veronesi","year":"1997","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.869864","article-title":"Axillary lymph node dissection can be omitted in breast cancer patients with mastectomy and false-negative frozen section in sentinel lymph node biopsy","volume":"12","author":"Si","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2005.11928044","article-title":"Survival analysis following sentinel lymph node biopsy: A validation trial demonstrating its accuracy in staging early breast cancer","volume":"18","author":"Carlo","year":"2005","journal-title":"Bayl Univ Med Cent Proc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313487","article-title":"Omitting axillary dissection in breast cancer with sentinel-node metastases","volume":"390","author":"De Boniface","year":"2024","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981\u201322023 AMAROS trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.14140","article-title":"Axillary lymph node dissection vs sentinel biopsy only among women with early-stage breast cancer and sentinel node metastasis: A systematic review and meta-analysis","volume":"27","author":"Peristeri","year":"2021","journal-title":"Breast J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-022-06458-8","article-title":"Axillary lymph node dissection vs. sentinel node biopsy for early-stage clinically node-negative breast cancer: A systematic review and meta-analysis","volume":"306","author":"Petousis","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (clin Res Ed)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (clin Res Ed)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4425-7","article-title":"Empirical comparison of publication bias tests in meta-analysis","volume":"33","author":"Lin","year":"2018","journal-title":"J Gen Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11866-w","article-title":"Preservation of axillary lymph nodes compared with complete dissection in T1\u20132 breast cancer patients presenting one or two metastatic sentinel lymph nodes: The SINODAR-ONE multicenter randomized clinical trial","volume":"29","author":"Tinterri","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5177-4","article-title":"Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial","volume":"23","author":"Canavese","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.12.011","article-title":"Eight-year follow up result of the OTOASOR trial: The optimal treatment of the axilla \u2013 surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer","volume":"43","author":"S\u00e1volt","year":"2017","journal-title":"Eur J Surg Oncol (ejso)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1406981","article-title":"The prognostic analysis of further axillary dissection in breast cancer with 1\u20132 positive sentinel lymph nodes undergoing mastectomy","volume":"14","author":"Zhao","year":"2024","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27503","article-title":"Patterns of completion axillary dissection for patients with cT1-2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes","volume":"129","author":"Schwieger","year":"2024","journal-title":"J Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"znae077","DOI":"10.1093\/bjs\/znae077","article-title":"De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1\u20132 N0 breast cancer treated with mastectomy: Nationwide registry study (BOOG 2013-07)","volume":"111","author":"De Wild","year":"2024","journal-title":"Br J Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.438","article-title":"Axillary lymph node dissection does not improve post-mastectomy overall or disease-free survival among breast cancer patients with 1\u20133 positive nodes","volume":"51","author":"Joo","year":"2019","journal-title":"Cancer Res Treat"},{"key":"B27","doi-asserted-by":"publisher","first-page":"19893","DOI":"10.1038\/s41598-021-99359-w","article-title":"Survival and recurrence with or without axillary dissection in patients with invasive breast cancer and sentinel node metastasis","volume":"11","author":"Sanvido","year":"2021","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7597","article-title":"Impact of axillary dissection among patients with sentinel node-positive breast cancer undergoing mastectomy","volume":"19","author":"Sun","year":"2021","journal-title":"J Natl Compr Cancer Netw : JNCCN"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05157-4","article-title":"Retrospectively validating the results of the ACOSOG Z0011 trial in a large asian Z0011-eligible cohort","volume":"175","author":"Jung","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11689","article-title":"Axillary dissection no axillary dissection in breast cancer patients with positive sentinel lymph node: A single institution experience","volume":"33","author":"Arisio","year":"2019","journal-title":"In Vivo"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.5750","article-title":"Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer","volume":"27","author":"Bilimoria","year":"2009","journal-title":"JCO"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3390\/cancers12092638","article-title":"How different are the molecular mechanisms of nodal and distant metastasis in luminal a breast cancer","volume":"12","author":"Lapcik","year":"2020","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-023-01560-1","article-title":"New techniques versus standard mapping for sentinel lymph node biopsy in breast cancer: A systematic review and meta-analysis","volume":"75","author":"Rocco","year":"2023","journal-title":"Updates Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy182","article-title":"TNM classification of Malignant tumors (breast cancer study group)","volume":"49","author":"Sawaki","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.amjsurg.2003.10.028","article-title":"Lymphatic mapping and sentinel lymphadenectomy for breast cancer","volume":"188","author":"Kelley","year":"2004","journal-title":"Am J Surg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-022-06556-7","article-title":"Can axillary lymphadenectomy be avoided in breast cancer with positive sentinel lymph node biopsy? Predictors of non-sentinel lymph node metastasis","volume":"306","author":"Alcaide","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled, phase 3 trial","volume":"19","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12893-023-02101-8","article-title":"Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: A systematic review and meta-analysis","volume":"23","author":"Fan","year":"2023","journal-title":"BMC Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810013391401","article-title":"The sentinel node in breast cancer \u2014 a multicenter validation study","volume":"339","author":"Krag","year":"1998","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41698-018-0047-0","article-title":"Organotropism: New insights into molecular mechanisms of breast cancer metastasis","volume":"2","author":"Chen","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/OP.21.00635","article-title":"Advances in breast cancer radiotherapy: Implications for current and future practice","volume":"17","author":"Shah","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(23)01082-6","article-title":"Radiotherapy to regional nodes in early breast cancer: An individual patient data meta-analysis of 14\u2013324 women in 16 trials","volume":"402","author":"Taylor","year":"2023","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.3390\/ijms23126806","article-title":"Breast cancer metastasis: Mechanisms and therapeutic implications","volume":"23","author":"Park","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3390\/cancers16040742","article-title":"Reevaluating axillary lymph node dissection in total mastectomy for low axillary burden breast cancer: Insights from a meta-analysis including the SINODAR-ONE trial","volume":"16","author":"Alamoodi","year":"2024","journal-title":"Cancers"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100\u2013000 women in 123 randomised trials","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet (lond Engl)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90125-3","article-title":"Role of adjuvant endocrine therapy in early-stage breast cancer","volume":"28","author":"Muss","year":"2001","journal-title":"Semin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1550003","article-title":"Tumor-infiltrating immune cells state-implications for various breast cancer subtypes","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21724","article-title":"Breast cancer recurrence risk can remain for 10 to 32 years","volume":"72","author":"Fillon","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34015","article-title":"Disease characteristics and mortality among asian women with breast cancer","volume":"128","author":"Yu","year":"2022","journal-title":"Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Msph","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary surgery in breast cancer \u2014 primary results of the INSEMA trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: The SOUND randomized clinical trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1620034\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:17:50Z","timestamp":1758773870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1620034\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":55,"alternative-id":["10.3389\/fonc.2025.1620034"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1620034","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1620034"}}